The median concentration of bortezomib required to inhibit TNFα production by 50% (IC50) was significantly higher in the RA patients than the healthy controls, while there was no significant difference between the IC50 of methotrexate [128]. The gene discussed is TNF; the disease is rheumatoid arthritis.